Pull to refresh
Logo
Daily Brief
Following Why Ranks Sign Up
First oral biologic for psoriasis reaches patients, opening new front in autoimmune treatment

First oral biologic for psoriasis reaches patients, opening new front in autoimmune treatment

New Capabilities

A once-daily pill that blocks interleukin-23 matches injectable biologic efficacy for the first time, with implications far beyond skin disease

March 18th, 2026: FDA approves ICOTYDE, first oral IL-23 blocker

Overview

For two decades, the most effective treatments for moderate-to-severe psoriasis required needles — self-injected drugs or clinic infusions that many patients refused or abandoned. On March 18, 2026, the Food and Drug Administration (FDA) approved ICOTYDE, a once-daily pill that blocks the interleukin-23 (IL-23) receptor with the precision of an injectable biologic. In clinical trials of roughly 2,500 patients, about 70 percent achieved clear or almost clear skin at 16 weeks, with side effects within 1.1 percentage points of a placebo.

The approval marks a structural shift in how autoimmune diseases can be treated. ICOTYDE is not a conventional small-molecule drug — it is an engineered peptide, a miniaturized biologic designed to survive the digestive tract and hit a single immune target. Developer Johnson & Johnson is already testing the same molecule in ulcerative colitis, Crohn's disease, and psoriatic arthritis, conditions that collectively affect tens of millions of people worldwide. If the pill works across those indications, it could reshape the $30-billion-plus autoimmune drug market away from injectable-first treatment.

Play on this story Voices Debate Predict

Key Indicators

~70%
Patients achieving clear or almost clear skin at 16 weeks
Measured by Investigator Global Assessment score of 0 or 1 across Phase 3 trials
1.1%
Adverse event difference versus placebo
Side effect rates were nearly indistinguishable from placebo through 52 weeks of treatment
125M
People with psoriasis worldwide
Approximately 2-3% of the global population, with roughly 30% also developing psoriatic arthritis
$5B+
Projected peak annual sales
Johnson & Johnson's internal target, positioning the drug as a successor to the biosimilar-threatened Stelara franchise
~2,500
Patients enrolled across four Phase 3 trials
ICONIC-LEAD, ICONIC-ADVANCE 1 and 2, and ICONIC-TOTAL trials

Interactive

Exploring all sides of a story is often best achieved with Play.

Ever wondered what historical figures would say about today's headlines?

Sign up to generate historical perspectives on this story.

Log in Sign Up

People Involved

Dinesh V. Patel
Dinesh V. Patel
Leading Protagonist through its first FDA approval and expanded pipeline
 Jennifer Taubert
Jennifer Taubert
Leading J&J's immunology commercial strategy
 Joaquin Duato
Joaquin Duato
Positioning ICOTYDE as key growth driver for 2026
 Mark Smythe
Mark Smythe
Developed the Vectrix peptide platform underlying ICOTYDE

Organizations Involved

Johnson & Johnson
Johnson & Johnson
Pharmaceutical and Medical Device Company
Developer and commercial partner for ICOTYDE

Global pharmaceutical and medical device company whose Janssen subsidiary developed ICOTYDE through Phase 3 trials and will handle worldwide commercialization.
Protagonist Therapeutics
Protagonist Therapeutics
Biotechnology Company
Originator of icotrokinra; earning milestones and royalties

Biotech company specializing in constrained oral peptides, whose Vectrix platform enabled the first oral biologic to reach FDA approval.
U.S. Food and Drug Administration
U.S. Food and Drug Administration
Federal regulatory agency
Approved ICOTYDE for moderate-to-severe plaque psoriasis

Federal agency responsible for evaluating and approving new drugs for the U.S. market.
Bristol Myers Squibb
Bristol Myers Squibb
Pharmaceutical Company
Maker of competing oral psoriasis drug Sotyktu, which ICOTYDE outperformed in head-to-head trials

Pharmaceutical company whose oral TYK2 inhibitor Sotyktu was the previous leading oral option for psoriasis until ICOTYDE demonstrated superiority in clinical trials.

Timeline

  1. FDA approves ICOTYDE, first oral IL-23 blocker

    Approval

    The FDA approved ICOTYDE (icotrokinra) for moderate-to-severe plaque psoriasis in adults and adolescents aged 12 and older. The first-in-class oral peptide targets the IL-23 receptor, previously reachable only by injectable biologics. Protagonist Therapeutics received a $50 million milestone payment.

  2. J&J submits New Drug Application to FDA

    Regulatory

    Johnson & Johnson filed its New Drug Application for icotrokinra, seeking approval for moderate-to-severe plaque psoriasis in adults and adolescents.

  3. ICOTYDE beats Sotyktu in head-to-head trials

    Clinical Trial

    Results from ICONIC-ADVANCE 1 and 2 showed icotrokinra was superior to deucravacitinib (Sotyktu), with 70 percent of patients achieving clear or almost clear skin versus roughly 40 percent for the competing oral drug.

  4. Phase 3 ICONIC program launches

    Clinical Trial

    Johnson & Johnson initiated the Phase 3 ICONIC clinical trial program for icotrokinra, enrolling approximately 2,500 patients across four studies: ICONIC-LEAD, ICONIC-ADVANCE 1 and 2, and ICONIC-TOTAL.

  5. Sotyktu approved as first oral TYK2 inhibitor

    Approval

    The FDA approved Bristol Myers Squibb's deucravacitinib (Sotyktu), the first oral TYK2 inhibitor for psoriasis. While closer to biologic efficacy than Otezla, it fell short of injectable standards.

  6. Protagonist and J&J strike billion-dollar deal

    Business

    Protagonist Therapeutics and Johnson & Johnson's Janssen subsidiary signed a worldwide exclusive license agreement for icotrokinra. Protagonist received $50 million upfront and became eligible for up to $940 million in milestones.

  7. Injectable IL-23-specific blockers arrive

    Approval

    Guselkumab (Tremfya) became the first IL-23-specific injectable biologic approved for psoriasis, followed by risankizumab (Skyrizi) in 2019. Both achieved skin clearance rates around 75-80 percent.

  8. First targeted oral psoriasis drug approved

    Approval

    The FDA approved apremilast (Otezla), a PDE4 inhibitor and the first targeted oral therapy for psoriasis. Its efficacy was modest compared to injectable biologics.

  9. Stelara approved, launching the IL-12/23 era

    Approval

    The FDA approved ustekinumab (Stelara), the first interleukin-12/23 blocker for psoriasis. The injectable drug eventually reached $11 billion in annual sales for Johnson & Johnson.

  10. First biologic therapies approved for psoriasis

    Milestone

    The FDA approved alefacept and efalizumab, the first biologic drugs for psoriasis. TNF-alpha inhibitors followed, transforming treatment but requiring injections or infusions.

Scenarios

Predict which scenario wins. Contrarian picks score more — points lock in when the scenario resolves.

Log in to predict. Track your picks, climb the leaderboard. Log in Sign Up
1

ICOTYDE captures first-line oral position, reaching $5 billion in peak sales

Dermatologists adopt ICOTYDE as the default first oral therapy for moderate-to-severe psoriasis, displacing Sotyktu and expanding the treated population by converting injection-averse patients. Payers cover the drug without onerous prior authorization given its biologic-level efficacy and clean safety profile. Successful Phase 3 readouts in ulcerative colitis and Crohn's disease by 2028 multiply the addressable market. Over 50 percent of surveyed dermatologists already rank it as their top pipeline agent, and 70 percent envision first-line use.

Discussed by: J&J leadership at the January 2026 JPMorgan Healthcare Conference; GlobalData analysts projecting blockbuster status by 2029
Consensus —
2

Biosimilar competition and payer pushback limit uptake

Low-cost biosimilars of Stelara and eventually other injectable IL-23 blockers flood the market, and insurance companies mandate these cheaper injectables as first-line therapy before covering ICOTYDE. The drug's 30-minute fasting requirement and the modest efficacy gap versus top injectables like Skyrizi give payers justification to restrict access. ICOTYDE becomes a niche option for patients who specifically refuse injections rather than a broad market standard. Sotyktu's commercial underperformance — $291 million in 2025 versus projected $4 billion peak — serves as a cautionary precedent.

Discussed by: Market analysts noting the 'cooler than expected' stock response on approval day; payer strategy consultants at Recon Strategy
Consensus —
3

Next-generation oral competitors erode ICOTYDE's lead within three years

Next-generation oral TYK2 inhibitors — Alumis's ESK-001 (envudeucitinib) and Takeda's zasocitinib — report Phase 3 results in 2026 that close the efficacy gap with ICOTYDE while potentially offering simpler dosing (no fasting requirement). If either matches or approaches ICOTYDE's skin clearance rates with comparable safety, the competitive landscape fragments before J&J can establish market dominance. The window for ICOTYDE to become the unchallenged oral standard narrows significantly.

Discussed by: Alumis and Takeda leadership presenting late-stage TYK2 inhibitor data; BioPharma Dive analysts
Consensus —
4

Oral biologics expand across autoimmune diseases, reshaping the treatment paradigm

ICOTYDE succeeds in Phase 3 trials for ulcerative colitis, Crohn's disease, and psoriatic arthritis, proving that oral IL-23 blockade works across multiple autoimmune conditions. Protagonist's pipeline of additional oral peptides — targeting IL-17, IL-4 receptor alpha, and GLP-1 — reaches clinical milestones. The combined effect shifts the default treatment paradigm for autoimmune diseases from injectable-first to oral-first, similar to how direct oral anticoagulants displaced warfarin and injectable heparin in cardiovascular medicine.

Discussed by: IQVIA analysts in their 2025 report on novel oral immunotherapies; J&J's immunology pipeline disclosures
Consensus —

Historical Context

Hepatitis C: From interferon injections to oral cure (2011-2014)

2011-2014

What Happened

For decades, hepatitis C was treated with interferon injections that caused severe flu-like side effects and cured fewer than half of patients. In 2013, Gilead Sciences launched Sovaldi (sofosbuvir), followed by Harvoni in 2014 — oral pills that cured hepatitis C in over 95 percent of patients within 8 to 12 weeks. Sovaldi generated $10.3 billion in its first full year on market.

Outcome

Short Term

Patient demand overwhelmed payer budgets. Sovaldi's $84,000 list price for a course of treatment triggered a national debate about drug pricing even as it cured a previously intractable disease.

Long Term

The injectable interferon market collapsed almost entirely. Hepatitis C treatment became a cure rather than a chronic management regimen. The precedent demonstrated that oral drugs with dramatically superior convenience could rapidly displace entrenched injectable standards.

Why It's Relevant Today

ICOTYDE faces a similar dynamic: an oral drug entering a market dominated by effective but burdensome injectable therapies. The hepatitis C precedent suggests that if the efficacy gap is small enough, patient and physician preference for oral convenience can drive rapid market transformation — but pricing will be a central battleground.

Oral semaglutide proves peptide pills are viable (2019)

September 2019

What Happened

Novo Nordisk won FDA approval for Rybelsus, the first oral formulation of a GLP-1 receptor agonist — the same class of drug as injectable Ozempic. The company used a novel absorption enhancer called SNAC to protect the peptide from stomach acid. Like ICOTYDE, Rybelsus required a 30-minute fast before eating.

Outcome

Short Term

Initial enthusiasm was high, with 77 percent of surveyed patients preferring the oral form. That preference dropped to 46 percent once patients learned about the fasting requirement — a real-world friction that limited adoption.

Long Term

Rybelsus proved oral peptide delivery was commercially viable at scale, de-risking the concept for companies like Protagonist Therapeutics. However, injectable semaglutide (Ozempic, Wegovy) ultimately grew faster, partly because the fasting requirement reduced the convenience advantage of the oral form.

Why It's Relevant Today

ICOTYDE faces the same fasting-requirement challenge as Rybelsus. The oral semaglutide experience suggests that a pill format alone does not guarantee market dominance — the real-world convenience must be meaningfully better than the injectable alternative, not just theoretically better.

Direct oral anticoagulants replace warfarin (2010-2020)

2010-2020

What Happened

Starting with dabigatran (Pradaxa) in 2010, a wave of direct oral anticoagulants — including rivaroxaban (Xarelto) and apixaban (Eliquis) — replaced warfarin, a drug that required constant blood monitoring, dietary restrictions, and careful dose titration. The new pills offered fixed dosing with no monitoring.

Outcome

Short Term

Adoption was rapid among cardiologists despite higher drug costs, driven by the dramatic reduction in monitoring burden for both patients and physicians.

Long Term

Within a decade, direct oral anticoagulants captured over 80 percent of new anticoagulant prescriptions. Eliquis became one of the world's best-selling drugs at over $20 billion annually. The transition demonstrated that reducing treatment burden can drive massive market shifts even when the new drugs are not clearly more effective.

Why It's Relevant Today

The anticoagulant transition is the clearest model for what ICOTYDE could achieve: a convenient oral alternative that captures market share primarily by reducing patient burden rather than by offering dramatically superior efficacy. The speed of the DOAC transition — under a decade to 80 percent share — suggests the psoriasis market could shift rapidly if payer barriers are manageable.

Sources

(10)
+4
STAT News PR Newswire (Johnson & Johnson) Fierce Pharma BioSpace New England Journal of Medicine Dermatology Times Yahoo Finance Johnson & Johnson Pharmaphorum BioSpace